



**HAL**  
open science

## **Emergence of resistant *Klebsiella pneumoniae* in the intestinal tract during successful treatment of *Klebsiella pneumoniae* lung infection in rats.**

Anne-Sylvie Kesteman, Agnès Perrin-Guyomard, Michel Laurentie, Pascal Sanders, Pierre-Louis Toutain, Alain Bousquet-mélou

### ► **To cite this version:**

Anne-Sylvie Kesteman, Agnès Perrin-Guyomard, Michel Laurentie, Pascal Sanders, Pierre-Louis Toutain, et al.. Emergence of resistant *Klebsiella pneumoniae* in the intestinal tract during successful treatment of *Klebsiella pneumoniae* lung infection in rats.. *Antimicrobial Agents and Chemotherapy*, 2010, 54 (7), pp.2960-4. 10.1128/AAC.01612-09 . hal-00517528

**HAL Id: hal-00517528**

**<https://hal.science/hal-00517528>**

Submitted on 16 Sep 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Emergence of resistant *Klebsiella pneumoniae* in the intestinal tract during a**  
2 **successful treatment of *Klebsiella pneumoniae* lung infection in rats.**

3

4 **Running Title:** Intestinal Impact of Fluoroquinolones

5

6

7 Anne-Sylvie Kesteman<sup>1,2</sup>, Agnès Perrin-Guyomard<sup>2</sup>, Michel Laurentie<sup>2</sup>, Pascal Sanders<sup>2</sup>,  
8 Pierre-Louis Toutain<sup>1</sup> and Alain Bousquet-Mélou<sup>1</sup>

9

10 <sup>1</sup> UMR181 Physiopathologie et Toxicologie Expérimentales, INRA, ENVT, Ecole Nationale  
11 Vétérinaire de Toulouse, 23 chemin des Capelles, BP 87614, 31076 Toulouse Cedex 3,  
12 France.

13

14 <sup>2</sup> Laboratory for the Research and Investigation of Veterinary Drugs and Disinfectants,  
15 AFSSA Fougères, La Haute Marche, BP 90203, Javené 35302 Fougères, France

16

17 Potential conflicts of interest: none

18 Financial support: grant from the Institut National de la Recherche Agronomique (INRA) and  
19 from the Agence Française de Sécurité Sanitaire des Aliments (AFSSA).

20 Corresponding author: Prof. Alain Bousquet-Mélou, Mailing address: UMR181  
21 Physiopathologie et Toxicologie Expérimentales, INRA, ENVT, Ecole Nationale Vétérinaire  
22 de Toulouse, 23 chemin des Capelles, BP 87 614, 31076 Toulouse Cedex 3, France. Phone:  
23 +33 (0)5.61.19.39.25. Fax: +33 (0)5.61.19.39.17. E-mail: a.bousquet-melou@envt.fr.

24

25 Abstract: 196 words

26 Text: 3008 words

27 **ABSTRACT**

28 Antibiotic treatment of lung infections may lead to the emergence of resistance in the gut  
29 flora. Appropriate dosing regimens could mitigate this adverse effect. In gnotobiotic rats  
30 harbouring intestinal *E. coli* and *E. faecium* populations, a lung infection by *K. pneumoniae*  
31 was instigated with two different sizes of inoculum to represent an early or a late initiation of  
32 antibiotic treatment. The rats were treated with marbofloxacin, a third generation  
33 fluoroquinolone by a single shot administration or a fractionated regimen over 4 days.  
34 Intestinal bacterial populations were monitored during and after treatment. At the infection  
35 site bacterial cure without any selection of resistance was observed. Whatever the dosage  
36 regimen, fluoroquinolone treatment had a transient negative impact on the gut *E. coli*  
37 population but not on that of *E. faecium*. The intestinal flora was colonized by the pathogenic  
38 lung bacteria and there was the emergence of intestinal resistant *K. pneumoniae*, occurring  
39 more often in animals treated with a single marbofloxacin dose than with the fractionated  
40 dose. Bacterial cure without resistance selection at the infection site with fluoroquinolone  
41 treatment can be linked to colonization of the digestive tract by the targeted pulmonary  
42 bacteria, followed by the emergence of resistance.

43

44 **Key words.**

45 Fluoroquinolones, Resistance, Intestinal flora, Dosage Regimen, Colonization.

## 46 INTRODUCTION

47 The emergence of antimicrobial resistance during antibiotic treatment can occur  
48 either in the infected organ system and/or in the endogenous normal gut flora (3).  
49 Antimicrobial agents including fluoroquinolones can be extensively excreted into the  
50 intestinal tract exposing the normal host flora to antimicrobial selective pressure (i.e.  
51 inhibition of competing microflora). This may lead to a secondary development of antibiotic-  
52 resistant gut organisms (2, 3, 17). *K. pneumoniae* is an important opportunistic pathogen  
53 implicated in nosocomial bacterial infections (19). Epidemiological studies have shown that  
54 the majority of *K. pneumoniae* infections are often preceded by colonization of the patient's  
55 gastrointestinal tract by the bacteria (9, 10). Recent reports suggest that fluoroquinolone-  
56 resistant *Klebsiella pneumoniae* isolates are common in many long-term care facilities and  
57 hospitals and are often associated with multidrug-resistant phenotypes (11, 22). The origins  
58 of this resistant *K. pneumoniae* gut subpopulation should deserve attention. A possible factor  
59 contributing to the emergence of a resistant subpopulation of *K. pneumoniae* in the gut could  
60 be an inadequate treatment of a prior *K. pneumoniae* infection with a secondary gut  
61 colonization by *K. pneumoniae*. This *K. pneumoniae* strain may then expand in the gut flora  
62 due to the selective pressure of the antibiotic reaching the gut lumen. Factors such as the  
63 concentration of the antimicrobial in the intestinal tract, the duration of the antimicrobial  
64 therapy, and the associated degree of disruption of the microflora may influence the  
65 likelihood that *K. pneumoniae* resistant strains will or will not emerge at the gut level (3, 21).  
66 In previous studies on rodent models of *E. coli* thigh infection and *K. pneumoniae* lung  
67 infection, we showed that the bacterial load at the start of antimicrobial treatment plays an  
68 important role in the enrichment of resistant strains at the infection site (4, 8). With a low  
69 inoculum, starting antimicrobial treatment early with marbofloxacin, a third generation  
70 fluoroquinolone extensively used in veterinary medicine, prevented mutant enrichment at the  
71 infection site whereas a late start of the antimicrobial treatment on a large inoculum, led to  
72 the enrichment of the resistant mutant subpopulation. Moreover, we showed that the

73 emergence of resistance was dependant on the total marbofloxacin dose and dosage  
74 regimen.

75 The aim of the present study was to assess, in a *K. pneumoniae* experimental infection  
76 model, the impact of different marbofloxacin dosage regimens on the commensal intestinal  
77 flora and to test the hypothesis that the critical site of emergence of resistance of a targeted  
78 lung pathogen during antibiotic treatment may be not the lung itself but the gut flora. With this  
79 as our aim, we developed a model of lung infection in gnotobiotic rats with two inoculum  
80 sizes of *K. pneumoniae* each treated with two different marbofloxacin dosage regimens. We  
81 chose to work with a gnotobiotic model harbouring a gram positive and a gram negative  
82 bacterial population in the intestine.

83 **MATERIALS AND METHODS.**

84 **Bacterial strains and antibiotics.**

85 The *Escherichia coli* and *Enterococcus faecium* strains used for the establishment of dixeric  
86 gut flora in rats came from pig samples from French slaughterhouses (AFSSA, Fougères)  
87 and *K. pneumoniae* ATCC 43 816 was used for the establishment of the lung infection.  
88 Marbofloxacin powder, was kindly provided by Vetoquinol, Lure, France.

89

90 ***Klebsiella pneumoniae* lung infection.**

91 Germ-free male OFA rats (Charles River, L'arbresle, France), weight 170-200g, were housed  
92 individually in different sterile isolators, with a 12-h-light/12-h-dark cycle. Rats were fed ad  
93 libitum with an irradiated rodent chow (R03 40, UAR, Villemoisson, France) and were  
94 supplied with sterilized distilled water.

95 The germ-free status of the rats was checked immediately after their reception and during  
96 the period of acclimatization (see bacteriological procedures). After about one week, the rats  
97 were inoculated intragastrically with 1 mL of a saline (0.9% NaCl) suspension of *E. coli*  
98 ( $10^9$  CFU/mL) strain and 1 mL of a saline (0.9% NaCl) suspension of *E. faecium*  
99 ( $10^9$  CFU/mL).

100 The experimental lung infection was produced as previously described (1, 8). Briefly, the  
101 trachea was cannulated and the lungs were inoculated with 0.05 mL of a saline suspension  
102 (0.9% NaCl) of *K. pneumoniae* containing  $2 \times 10^6$  CFU/mL ( $10^5$  CFU total, Group A) or  
103  $2 \times 10^9$  CFU/mL ( $10^8$  CFU total, Group B).

104 All animal procedures were conducted in accordance with accepted standards of animal care  
105 under the agreement number A 31909 for animal experimentation from the French Ministry of  
106 Agriculture.

107

108 **Antimicrobial treatment.**

109 Subcutaneous marbofloxacin treatment (Marbocyl<sup>ND</sup>, Vetoquinol, Lure, France) was started 4  
110 hours (Group A) or 24 hours (Group B) after the lung infection. There were two modalities of

111 treatment: doses were administered either in one single administration (Groups A1 and B1,  
112 n = 10 and n = 7 respectively) or the same total dose was fractionated into 4 daily  
113 administrations over 4 days (Groups A2 and B2, n = 8 and n = 7 respectively). The total  
114 marbofloxacin dose was 16 mg/kg, for group A and 64 mg/kg for group B. Stool samples  
115 were collected at day 0, 4 and 7 after the first marbofloxacin administration for bacterial  
116 analyses. The animals were sacrificed 7 days after the first marbofloxacin administration by  
117 an intraperitoneal injection of sodium pentobarbital (Dolethal<sup>ND</sup>, Vetoquinol, France). The  
118 lungs were aseptically removed and homogenized in 10 mL of 0.9% NaCl before  
119 bacteriological analysis.

120

#### 121 **Bacteriological procedures.**

122 **(i) MIC determination.** MICs were determined in triplicate for the bacteria by a broth micro  
123 dilution method according to CLSI references methods.

124

125 **(ii) Faecal bacteriology.** Stool samples were diluted tenfold in distilled water and  
126 homogenized. The germ-free status was verified on Schaedler agar supplemented with  
127 sheep blood, Brain Heart Infusion (BHI) agar supplemented with sheep blood; and Malt  
128 Extract Agar. During the study, 100  $\mu$ L of faecal homogenates collected at days 0, 4 and 7  
129 after the start of marbofloxacin treatment were plated on Slanetz and Bartley Medium for the  
130 *E. faecium* strain, on Mac Conkey Agar for the *E. coli* strain, and on Mac Conkey Agar  
131 supplemented with 0.3  $\mu$ g/mL of marbofloxacin for resistant *E. coli*. and colonies were  
132 counted after 24 hours incubation at 37°C for *E. coli* and 48 hours for *E. faecium*. The lowest  
133 level of detection was 100 CFU/g faeces.

134

135 **(iii) Lung bacteriology.** Lung homogenates were plated on drug-free Mueller Hinton agar  
136 plates containing 10% activated charcoal and 10% MgSO<sub>4</sub> to enumerate total bacterial  
137 counts of *K. pneumoniae* and on Mac Conkey agar supplemented with 0.3  $\mu$ g/mL  
138 marbofloxacin to enumerate bacterial counts of resistant *K. pneumoniae*. Colonies were

139 counted after overnight incubation at 37°C. The lowest level of detection was 100 CFU/lung  
140 and bacteria were considered eradicated below this level.

#### 141 **Pharmacokinetics.**

142 Two satellite groups (Group C and D) of conventional male OFA rats (Charles River,  
143 L'arbresle, France), weight 250-270g, were inoculated with 0.05 mL of an inoculum of  
144  $2 \times 10^6$  CFU/mL (Group C) or  $2 \times 10^{10}$  CFU/mL (Group D) of *K. pneumoniae*. Four hours  
145 after the inoculation, group C was given 4 or 16 mg/kg of marbofloxacin by subcutaneous  
146 administration. For the group D, subcutaneous marbofloxacin administration was 24 hours  
147 after the *K. pneumoniae* inoculation and was 4, 16 or 100 mg/kg. The total amount of  
148 excreted faeces was collected over 48 hours. Two to four rats were included per treatment  
149 group. Stool samples were stored at -20°C until assayed for marbofloxacin by a high  
150 performance liquid chromatography method with fluorescence detection ( $\lambda_{exc} = 295$  nm,  $\lambda_{em} =$   
151 500 nm) (Agilent 1100) adapted from Schneider et al. (18). Briefly, for each sample time,  
152 faeces were pooled, mixed with 2.5% trichloroacetic acid and centrifuged. The supernatant  
153 was added to 1 mL of dichloromethane and mixed for 10 seconds. 0.2 mL of a mixture of  
154 MeOH (2% HCl)/H<sub>2</sub>O (90:10) was added to the organic layer and 100  $\mu$ L of the supernatant  
155 were injected into a C18e (Lichrospher, Merck, 5  $\mu$ m 125x4 mm) column and eluted with a  
156 phosphoric acid (0.01M)-triethylamine(0.004M) (pH = 2)/Acetonitrile gradient. The calibration  
157 curve of marbofloxacin was established over the concentration range from 550 to  
158 5000 ng/mL with a linear regression model. The accuracy varied from 94.8 to 113.87% and  
159 the intra-day and inter-day precision was lower than 10.51% and 7.7% respectively. The limit  
160 of quantification was 550 ng/mL. The samples were diluted to ensure that the concentrations  
161 fell within the range of the calibration curve.

## 162 **RESULTS AND DISCUSSION**

### 163 **Susceptibility studies.**

164 The MIC of marbofloxacin was 0.032 µg/mL for both *K. pneumoniae* and *E. coli* and 2 µg/mL  
165 for *E. faecium*.

166

### 167 **Faecal Pharmacokinetics.**

168 Bacterial infections have been shown to alter the pharmacokinetics of drugs (5), including  
169 fluoroquinolones (7, 13). For this reason, we evaluated the amount of marbofloxacin excreted  
170 in the faeces in our model of *K. pneumoniae* lung infection. We observed that the amount of  
171 marbofloxacin excreted in the faeces of rats was proportional to the dose within each animal  
172 group (A or B), but differed between groups: the percentage of the marbofloxacin dose  
173 excreted in faeces was 4-fold less for the animals infected with the large *K. pneumoniae*  
174 inoculum than for those infected with the low inoculum (mean = 5% vs. 23% respectively, see  
175 Table 1). Consequently, taking into account the fact that groups B received a four times  
176 higher marbofloxacin dose than groups A (64 vs. 16 mg/kg), the amount of marbofloxacin  
177 excreted in the faeces was approximately the same in the two groups.

178

### 179 **Effect of different marbofloxacin dosage regimens on survival rate and on the** 180 **emergence of resistant *K. pneumoniae* in the lungs.**

181 The amount of *K. pneumoniae* in each rat's lung and the percentage of animals with resistant  
182 *K. pneumoniae* at the end of the experiment for the two initial inoculum sizes and the  
183 different dosing regimens are shown in Table 2. All the rats infected with the low *K.*  
184 *pneumoniae* inoculum survived (groups A), and seven days after the start of the antimicrobial  
185 treatment, bacteria were not detected in the lungs of all the rats (except two) whatever the  
186 dosing regimen. For the rats infected with the high *K. pneumoniae* inoculum (groups B), the  
187 survival rate differed slightly according to the dosage regimen and was higher for the animals  
188 treated with the fractionated marbofloxacin regimen (group B2) than for animals treated with  
189 the one-shot dose (group B1). Nevertheless, the total bacterial population in the surviving

190 animals seven days after the start of antimicrobial treatment was almost the same for the two  
191 dosing regimens.

192 More importantly, whatever the dosage regimen, there were no *K. pneumoniae* resistant to  
193 marbofloxacin at the end of the trial, neither in the lungs of animals infected with the low *K.*  
194 *pneumoniae* inoculum (groups A1 and A2) or in those infected with the large inoculum  
195 (groups B1 and B2). These results differ from our previous results showing the emergence  
196 of *K. pneumoniae* resistant to 0.3 µg/mL marbofloxacin in the animals infected by a large  
197 inoculum and treated with 64 mg/kg of marbofloxacin (8). However, the present study was  
198 longer and we observed rat mortality within the large inoculum group (groups B) during the  
199 64 mg/kg marbofloxacin treatment, in contrast to the previous study. This mortality was  
200 probably due to a higher sensitivity to the infection of gnotobiotic animals compared to  
201 conventional rats. The animals that died during the treatment were possibly carriers of  
202 resistant *K. pneumoniae* in the lungs (data not checked).

203

#### 204 **Effect of different marbofloxacin dosage regimens on faecal microflora.**

205 For all animals, whatever the dosage regimen, the *E. faecium* population remained  
206 unchanged during and after the marbofloxacin treatment (Figure 1, panel A). Unfortunately,  
207 an evaluation of a resistant *E. faecium* population was not carried out due to an interaction  
208 between marbofloxacin and Slanetz and Bartley culture medium.

209 For the *E. coli* population a decrease in the number of isolates was observed during the  
210 treatment in all groups depending on both the marbofloxacin dose and the dosing regimen.  
211 This decrease was followed by an increase to pre-treatment levels after termination of the  
212 therapy (Figure 1, panel B). Seven days after the initiation of marbofloxacin treatment, a  
213 resistant *E. coli* subpopulation (MIC ranging from 0.256 to 2 µg/mL) was found in all  
214 treatment groups. The percentage of rats harbouring resistant intestinal *E. coli* was between  
215 10 and 17% for groups A1, A2 and B2, and only the group B1 (high dose, single shot)  
216 showed a higher percentage at 50% (Table 3). The fact that the amount of marbofloxacin  
217 excreted in the faeces was approximately the same in the two groups (groups A and B) could

218 explain why the numbers of animals with resistant *E. coli* in their faeces were rather similar  
219 for the different groups whatever the marbofloxacin total dose and regimens (single or  
220 fractionated administrations, see Table 3). Nevertheless it was difficult to correlate the  
221 emergence of resistant *E. coli* with the marbofloxacin concentration in the faeces since  
222 marbofloxacin could be highly bound to faecal matter (12).

223 However, the most important result of this study was the intestinal colonization by the  
224 targeted pathogenic bacteria, *K. pneumoniae*, present at the infection site. This *K.*  
225 *pneumoniae* colonization was established throughout the study and seven days after the  
226 start of antimicrobial treatment, it was observed in the majority of surviving animals for the  
227 groups treated with a single administration (60% and 100% for the low and the high dose  
228 respectively) (Table 3 and Figure 1, panel C). Deglutition by the infected animals of *K.*  
229 *pneumoniae* moving out of the lung to the mucus escalator was probably the cause of the  
230 colonization of the intestinal tract by *K. pneumoniae*.

231 More importantly, intestinal colonization by *K. pneumoniae* was accompanied by the  
232 emergence in the gut of a *K. pneumoniae* subpopulation resistant to the fluoroquinolone.  
233 Faecal *K. pneumoniae* resistant to 0.3 µg/mL marbofloxacin (MIC ranging from 0.512 to  
234 2 µg/mL) were detected in 57% (8/14) of rats receiving a single dose (16 or 64 mg/kg)  
235 whatever the dose level (Table 3). For animals receiving the fractionated marbofloxacin  
236 administration, only one out of 14 rats carried a resistant *K. pneumoniae* subpopulation in the  
237 gut (Table 3). It is noteworthy that emergence of resistant *K. pneumoniae* in the intestinal  
238 tract occurred in animals harbouring no resistant *K. pneumoniae* in their lungs. This intestinal  
239 colonization by resistant *K. pneumoniae* occurred in 54% of all surviving rats (15/28) and  
240 seemed to be slightly more frequent in groups infected with the high inoculum (8/10 i.e. 80%,  
241 Table 3) than with the low inoculum (7/18 i.e. 39%, Table 3). The most likely reason is that  
242 the probability of colonizing the intestinal tract increases with the inoculum size in the lung  
243 (more *K. pneumoniae* and more mucus production).

244 Furthermore, whatever the size of *K. pneumoniae* pulmonary inoculum, we observed a  
245 higher percentage of intestinal colonization by resistant *K. pneumoniae* when the treatment

246 was a single dose administration of marbofloxacin rather than the fractionated administration  
247 of the same total dose (8/14 i.e. 57% for single vs. 1/14 i.e. 7% for fractionated, Table 3). In a  
248 previous study, we showed that the antibiotic exposure played an important role in the  
249 selection of resistant bacteria at the infection site (8), and in agreement with the present  
250 results, we also showed that the plasma antibiotic exposure with fractionated administration  
251 limited the enrichment of the resistant subpopulation compared with the single administration  
252 of the same total marbofloxacin dose.

253 However the design of the present study did not enable us to document whether the  
254 emergence of the resistant *K. pneumoniae* subpopulation occurred in the digestive tract or in  
255 the lungs, but some clues suggest the emergence of resistance in the gut. Indeed, we  
256 observed resistant *K. pneumoniae* in the gut of animals harbouring no resistant *K.*  
257 *pneumoniae* in their lungs. Moreover, for animals infected with the low inoculum and treated  
258 by the single administration of 16 mg/kg of marbofloxacin, the size of the *K. pneumoniae*  
259 population in the gut was higher than the population inoculated into the lungs  
260 ( $8.1 \pm 1.1 \log_{10}$  CFU/g of faeces vs.  $5 \log_{10}$  CFU/lung, Table 3), increasing the likelihood of  
261 resistant mutants appearing in this intestinal bacterial population. Therefore the scenario of  
262 the intestinal colonization by wild type *K. pneumoniae* followed by the appearance in the gut  
263 of resistant *K. pneumoniae* mutants secondarily selected by marbofloxacin intestinal  
264 exposure seems more probable than the gut colonization by resistant *K. pneumoniae* of  
265 pulmonary origin.

266 We are not in a position to estimate the exact antibiotic exposure in the gut; but it is likely that  
267 the dosing regimens that are optimised to achieve clinical success while minimising the  
268 emergence of resistance at the lung infection site may actually be inappropriate in terms of  
269 gut colonization and intestine-located emergence of resistance.

270

## 271 **Conclusion.**

272 For the sake of simplicity, the present study was carried out with an artificial intestinal  
273 ecosystem in di-associated gnotobiotic rats, i.e. a system lacking anaerobes that can play an

274 important role in colonization resistance (20). However, this animal model appears to be  
275 relevant to the study of intestinal colonization by resistant bacteria given that anaerobic flora  
276 could be decreased in patients by some antimicrobial treatments. Therefore, such a model  
277 represents an alternative to classical models of intestinal colonization by resistant pathogenic  
278 bacteria, where anaerobic flora are eradicated by clindamycin treatment before colonization  
279 challenge (6, 15). To our knowledge, this study is the first using a model of natural gut  
280 colonization by pathogenic bacteria from a non-intestinal infection site, and showing the  
281 emergence of resistant strains in this new intestinal population during fluoroquinolone  
282 treatment of a lung infection. Indeed, usually studies on intestinal colonization use orogastric  
283 gavage of bacteria already resistant to the antibiotic (6, 14).

284 In conclusion, the results of the present study highlight that a fluoroquinolone  
285 treatment leading to the bacterial cure and prevention of resistance emerging at the infection  
286 site might at the same time lead to the emergence of resistant pathogenic bacteria in the  
287 digestive tract secondary to intestinal colonization by wild type pathogens. This could  
288 generate a reservoir of resistant pathogens for secondary infections (16, 23). In addition it  
289 was shown that such an event is influenced, and thus might be manageable, by the dosage  
290 regimen. This is a difficult challenge because antibiotic exposure to prevent the emergence  
291 of resistance in a pathogen should not only apply to the target site of infection but should be  
292 extended to the gut flora when colonization occurs.

293 **ACKNOWLEDGMENTS**

294 We thank Jacqueline Manceau for doing analytical assays, and Annick Brault, Mireille  
295 Bruneau, Pamela Louâpre, Stephane Marteau, Catherine Poirier and Jean-Guy Rolland for  
296 technical support.

297 **TABLE 1**

298 Amount of marbofloxacin excreted in the faeces of rats infected with a low or a high  
 299 inoculum.

Marbofloxacin dose (mg/kg)	Marbofloxacin administered ( $\mu\text{g}$ , mean $\pm$ SD)	Amount of marbofloxacin excreted in faeces ( $\mu\text{g}$ , mean $\pm$ SD)	
		Low inoculum Group A	High inoculum Group B
4	835 $\pm$ 58	129 $\pm$ 24	42 $\pm$ 23
16	3605 $\pm$ 232	896 $\pm$ 116	168 $\pm$ 126
100	22650 $\pm$ 636	nd	1340 $\pm$ 547

300 nd: not determined

301

302

303 **TABLE 2.**

304 Amount of *K. pneumoniae* in each rat lung and proportion of animals with resistant *K.*  
 305 *pneumoniae* at the end of the experiment for the low (Group A) and the high (Group B)  
 306 inocula.

Total marbofloxacin dose regimen Animal group	Low inoculum 16 mg/kg		High inoculum 64 mg/kg	
	Single A1	Fractionated A2	Single B1	Fractionated B2
<i>n</i>	10	8	7	7
No of dead animals	0	0	3	1
No of rats with <i>K. pneumoniae</i> in lungs at the end of experiment	1	1	4	6
total log <sub>10</sub> cfu/lungs (mean $\pm$ SD)	0.1 $\pm$ 0.2 <sup>b</sup>	0.3 $\pm$ 0.8 <sup>b</sup>	5.7 $\pm$ 2.0 <sup>a</sup>	5.9 $\pm$ 1.8 <sup>a</sup>
No of rats with resistant <i>K. pneumoniae</i> in lungs at the end of experiment	0	0	0 <sup>a</sup>	0 <sup>a</sup>

307

308 <sup>a</sup> Dead rats are not taken into consideration to calculate the total bacterial population in lungs

309 <sup>b</sup> For the calculation of these means, we assigned the value 0 log<sub>10</sub> CFU to the lungs in which

310 bacteria were undetectable.

311 **TABLE 3.**

312 Percentage of surviving rats with the intestinal tract colonized by *E. coli* resistant to marbofloxacin, wild-type *K. pneumoniae* or *K. pneumoniae*  
 313 resistant to marbofloxacin and amount of each population in faeces 4 and 7 days after the start of marbofloxacin treatment.


314

Inoculum size	Group	Total marbofloxacin dose and dosing regimen	4 days after initiation of marbofloxacin treatment						7 days after initiation of marbofloxacin treatment					
			<i>E. coli Resistant</i>		<i>K. pneumoniae Total</i>		<i>K. pneumoniae Resistant</i>		<i>E. coli Resistant</i>		<i>K. pneumoniae Total</i>		<i>K. pneumoniae Resistant</i>	
			No. of animals with bacteria in faeces/total no. animals	log <sub>10</sub> CFU/g of faeces (mean ± SD)	No. of animals with bacteria in faeces/total no. animals	log <sub>10</sub> CFU/g of faeces (mean ± SD)	No. of animals with bacteria in faeces/total no. animals	log <sub>10</sub> CFU/g of faeces (mean ± SD)	No. of animals with bacteria in faeces/total no. animals	log <sub>10</sub> CFU/g of faeces (mean ± SD)	No. of animals with bacteria in faeces/total no. animals	log <sub>10</sub> CFU/g of faeces (mean ± SD)	No. of animals with bacteria in faeces/total no. animals	log <sub>10</sub> CFU/g of faeces (mean ± SD)
LOW	A1	16 mg/kg - Single	0/10 (0%)	-	2/10 (20%)	5.0 ± 3.2	0/10 (0%)	-	1/10 (10%)	3.8 <sup>a</sup>	6/10 (60%)	8.1 ± 1.1	4/10 (40%)	3.8 ± 1.5
	A2	16 mg/kg - Fractionated	0/8 (0%)	-	0/8 (0%)	-	0/8 (0%)	-	1/8 (13%)	3.9 <sup>a</sup>	1/8 (13%)	5.7*	0/8 (0%)	-
HIGH	B1	64 mg/kg - Single	0/6 (0%)	-	5/6 (83%)	3.1 ± 2.4	3/6 (50%)	1.4 ± 1.9	2/4 (50%)	2.0 ± 0	4/4 (100%)	7.3 ± 1.3	4/4 (100%)	5.4 ± 0.1
	B2	64 mg/kg - Fractionated	0/6 (0%)	-	1/6 (17%)	1.7*	0/6 (0%)	-	1/6 (17%)	6.0 <sup>a</sup>	4/6 (67%)	5.9 ± 0.6	1/6 (17%)	1.7 <sup>a</sup>

315

316 <sup>a</sup>Only one animal of this group had bacteria in the faeces

317 **Figure 1.** Time course evolution of the levels of the total *E. faecium* (A), *E. coli* (B) and *K.*  
 318 *pneumoniae* (C) populations in the faeces of rats (Mean  $\pm$  SD) before, during and after  
 319 marbofloxacin treatment. The arrow shows the day of the lung infection.  
 320



321 REFERENCES

322

- 323 1. Bakker-Woudenberg, I. A., J. Y. de Jong-Hoenderop, and M. F. Michel. 1979.  
 324 Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of  
 325 impaired phagocytosis. *Infect Immun* 25:366-75.
- 326 2. Bourgeois-Nicolaos, N., L. Massias, B. Couson, M. J. Butel, A. Andremont, and F.  
 327 Doucet-Populaire. 2007. Dose dependence of emergence of resistance to linezolid  
 328 in *Enterococcus faecalis* in vivo. *J Infect Dis* 195:1480-8.
- 329 3. Donskey, C. J. 2004. The role of the intestinal tract as a reservoir and source for  
 330 transmission of nosocomial pathogens. *Clin Infect Dis* 39:219-26.
- 331 4. Ferran, A. A., A. S. Kesteman, P. L. Toutain, and A. Bousquet-Melou. 2009.  
 332 Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on  
 333 the selection of resistance in *Escherichia coli* by a quinolone in a mouse thigh  
 334 bacterial infection model. *Antimicrob Agents Chemother* 53:3384-90.
- 335 5. Hasegawa, T., K. Takagi, and K. Kitaichi. 1999. Effects of bacterial endotoxin on  
 336 drug pharmacokinetics. *Nagoya J Med Sci* 62:11-28.
- 337 6. Hoyen, C. K., N. J. Pultz, D. L. Paterson, D. C. Aron, and C. J. Donskey. 2003.  
 338 Effect of parenteral antibiotic administration on establishment of intestinal  
 339 colonization in mice by *Klebsiella pneumoniae* strains producing extended-  
 340 spectrum beta-lactamases. *Antimicrob Agents Chemother* 47:3610-2.
- 341 7. Ismail, M., and Y. A. El-Kattan. 2007. Comparative pharmacokinetics of  
 342 marbofloxacin in healthy and *Mannheimia haemolytica* infected calves. *Res Vet*  
 343 *Sci* 82:398-404.
- 344 8. Kesteman, A. S., A. A. Ferran, A. Perrin-Guyomard, M. Laurentie, P. Sanders,  
 345 P. L. Toutain, and A. Bousquet-Melou. 2009. Influence of inoculum size and  
 346 marbofloxacin plasma exposure on the amplification of resistant subpopulations  
 347 of *Klebsiella pneumoniae* in a rat lung infection model. *Antimicrob Agents*  
 348 *Chemother* 53:4740-8.
- 349 9. Martins, I. S., C. L. Pessoa-Silva, S. A. Nouer, E. G. Pessoa de Araujo, A. L.  
 350 Ferreira, L. W. Riley, and B. M. Moreira. 2006. Endemic extended-spectrum  
 351 beta-lactamase-producing *Klebsiella pneumoniae* at an intensive care unit: risk  
 352 factors for colonization and infection. *Microb Drug Resist* 12:50-8.
- 353 10. Montgomerie, J. Z. 1979. Epidemiology of *Klebsiella* and hospital-associated  
 354 infections. *Rev Infect Dis* 1:736-53.
- 355 11. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Karam, and  
 356 J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US  
 357 intensive care units: implications for fluoroquinolone use. *JAMA* 289:885-8.
- 358 12. Pellet, T., M. Gicquel-Bruneau, P. Sanders, and M. Laurentie. 2006. Comparison  
 359 of faecal and optimal growth conditions on in vitro pharmacodynamic activity of  
 360 marbofloxacin against *Escherichia coli*. *Res Vet Sci* 80:324-35.
- 361 13. Peyrou, M., M. Y. Doucet, A. Vrins, D. Concordet, M. Schneider, and A.  
 362 Bousquet-Melou. 2004. Population pharmacokinetics of marbofloxacin in horses:  
 363 preliminary analysis. *J Vet Pharmacol Ther* 27:283-8.
- 364 14. Pultz, M. J., M. M. Nerandzic, U. Stiefel, and C. J. Donskey. 2008. Emergence  
 365 and acquisition of fluoroquinolone-resistant gram-negative bacilli in the  
 366 intestinal tracts of mice treated with fluoroquinolone antimicrobial agents.  
 367 *Antimicrob Agents Chemother* 52:3457-60.
- 368 15. Pultz, N. J., U. Stiefel, and C. J. Donskey. 2005. Effects of daptomycin, linezolid,  
 369 and vancomycin on establishment of intestinal colonization with vancomycin-

- 370 resistant enterococci and extended-spectrum-beta-lactamase-producing  
371 *Klebsiella pneumoniae* in mice. *Antimicrob Agents Chemother* 49:3513-6.
- 372 16. Richard, P., M. H. Delangle, F. Raffi, E. Espaze, and H. Richet. 2001. Impact of  
373 fluoroquinolone administration on the emergence of fluoroquinolone-resistant  
374 gram-negative bacilli from gastrointestinal flora. *Clin Infect Dis* 32:162-6.
- 375 17. Safdar, N., and D. G. Maki. 2002. The commonality of risk factors for nosocomial  
376 colonization and infection with antimicrobial-resistant *Staphylococcus aureus*,  
377 enterococcus, gram-negative bacilli, *Clostridium difficile*, and *Candida*. *Ann*  
378 *Intern Med* 136:834-44.
- 379 18. Schneider, M., V. Thomas, B. Boisrame, and J. Deleforge. 1996.  
380 Pharmacokinetics of marbofloxacin in dogs after oral and parenteral  
381 administration. *J Vet Pharmacol Ther* 19:56-61.
- 382 19. Spencer, R. C. 1996. Predominant pathogens found in the European Prevalence  
383 of Infection in Intensive Care Study. *Eur J Clin Microbiol Infect Dis* 15:281-5.
- 384 20. Stecher, B., and W. D. Hardt. 2008. The role of microbiota in infectious disease.  
385 *Trends Microbiol* 16:107-14.
- 386 21. Sullivan, A., C. Edlund, and C. E. Nord. 2001. Effect of antimicrobial agents on  
387 the ecological balance of human microflora. *Lancet Infect Dis* 1:101-14.
- 388 22. Wiener, J., J. P. Quinn, P. A. Bradford, R. V. Goering, C. Nathan, K. Bush, and  
389 R. A. Weinstein. 1999. Multiple antibiotic-resistant *Klebsiella* and *Escherichia*  
390 *coli* in nursing homes. *JAMA* 281:517-23.
- 391 23. Yagci, D., F. Yoruk, A. Azap, and O. Memikoglu. 2009. Prevalence and risk  
392 factors for selection of quinolone-resistant *Escherichia coli* strains in fecal flora  
393 of patients receiving quinolone therapy. *Antimicrob Agents Chemother* 53:1287-  
394 9.
- 395  
396  
397

